Celularity Inc. - SIC # 8000 -

Ticker Exchange SIC # Website Latest Ticker
CELU Nasdaq 8000 www.celularity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celularity Inc.

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law - Jul 9th, 2025 6:30 am
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies - Jul 1st, 2025 6:30 am
Celularity Announces Chief Financial Officer Transition - Jun 10th, 2025 2:15 pm
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology - Jun 2nd, 2025 6:00 am
Celularity Receives Nasdaq Notice Regarding Form 10-Q - May 30th, 2025 3:30 pm
Celularity Announces Full Year 2024 Operating and Financial Results - May 9th, 2025 7:15 am
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - Apr 25th, 2025 3:30 pm
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - Apr 14th, 2025 6:00 am
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology - Apr 7th, 2025 6:00 am
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - Feb 25th, 2025 6:00 am
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - Feb 24th, 2025 6:00 am
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs - Jan 27th, 2025 6:00 am
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - Dec 10th, 2024 6:00 am
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 - Dec 6th, 2024 6:00 am
Celularity Inc. Announces Receipt of Nasdaq Notification - Nov 27th, 2024 3:00 pm
Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific - Nov 20th, 2024 6:30 am
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million - Nov 7th, 2024 6:00 am
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel - Oct 23rd, 2024 6:30 am
Celularity Provides Corporate Update - Oct 22nd, 2024 6:30 am
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - Oct 18th, 2024 4:00 pm